Excerpts

Kaplan Meier analysis considering tumor size exceeding 800 mm 3 as an endpoint showed a highly significant difference between curves ( p = 0.001) ( Figure 6 A,B).

Notably, HBP morphology did not reach statistical significance, while N1 status or higher was a predictor of poor RFS (2.85 (1.50–5.40), p = 0.001) and OS (1.73 (0.79–3.79), p = 0.004), and intrahepatic metastasis was a predictor of poor RFS (2.53 (1.34–4.75), p = 0.004). 4.

Overall, the effect of the intervention remained highly significant after accounting for clustering by site (χ 2 = 55.16, p < 0.001). 4.

Tumor Subsite Tumor anatomic distribution showed a highly significant difference between NSND and SD patients ( p < 0.001).

Case 8 showed highly significant changes ( p < 0.001) in size-related parameters (nuclear area, equivalent diameter, and circumference) and density measures, except for the area and diameter between the second and third recurrence ( Figure 7 a).

The log-rank test indicates a highly significant result, with p < 0.001.

Significant differences in eGFR were observed after cycles 1 through 3, with highly significant reductions emerging from cycle 4 onward (all p < 0.001).

The pooled OR from the random-effects model is 1.53, with a 95% CI of 1.107 to 1.945 and a highly significant p -value of <0.001.

High-risk tumor depths (≥4 mm) demonstrated a markedly significant negative dependence on both phosphorylated SMAD2 (C.C −0.214; p = 0.001) and SMAD3 (C.C −0.200; p = 0.002), which is consistent with a tumor-suppressive role for SMAD2/3 activators in cSCC [ 41 ].

Highly significant differences ( p < 0.001) were observed for TP53, APC, KRAS, TCF7L2 , and PIK3CA , followed by additional signals involving SMAD4, BRAF, PIK3R1 , and NF1 .

The overall pooled effect was highly significant (Z = 8.77, p < 0.001).

The ulceration status was significantly different between R1 and R2 ( p = 0.008) and showed a highly significant difference between R1 and R3 ( p < 0.001), but not between R2 and R3 ( p = 0.19).

They found a highly significant difference in both HPV-associated OPSCC DSS (log-rank p < 0.001) and PFS (log-rank p < 0.001), with higher TIL levels linked to longer survival.

Subgroup Analysis Age stratification: Overall the age did not impact the outcome; however older patients aged > 60 years with positive ctDNA at baseline had a slight trend towards poor PFS compared to ctDNA negative patients [pHR = 1.62; 95%CI: 0.72–2.52, p < 0.001; I 2 = 71.28%], while younger patients (age ≤60 years) showed no difference ([pHR = 1.11; 95%CI: 0.39–1.84, p < 0.001; I 2 = 98.26%]; Supplementary Figure S3a ).

Kaplan–Meier curves showed highly significant ( p < 0.001) reduced DFS in patients with SAAR ≥ 2 compared to those with SAAR < 2 ( Figure 3 ).

Statistical analysis conducted using the log-rank test further confirmed that the difference in survival between the two groups was highly significant ( p < 0.001). 3.5.

In addition, patients classified to the highest EASIX-FC risk group showed a trend for increased incidence of ICANS grade 3 to 4 that reached 60% (HR, 3.8; p < 0.001).

Differences in the presence and extent of tumors between the E2 + P4- and placebo-treated mice in both the BPRN -homo and BPRN -het groups were highly significant ( p < 0.001 and p < 0.001, respectively).

Subgroup analyses focusing on mid/distal tumor locations and cTNM stages II/III indicated a significant trend towards improved survival with NAC (all p < 0.001).

In the Chi-square test, the OSCC tissue samples showed a highly significant upregulation of CD96 mRNA expression ( p < 0.001) and protein expression ( p = 0.005) compared to the healthy mucosa.

As for the Non-Diab group, we found an increasing trend for non-Hodgkin lymphoma [APC: 3.23% (1.25–5.15%), p = 0.0011] and thyroid [APC: 3.07% (0.67–5.38%), p = 0.0112] cancers, and a decreasing trend for gallbladder [APC: −6.04% (−8.98–−3.20%), p < 0.0001], stomach [APC: −5.25% (−7.12–−3.43%), p < 0.0001], colorectal [APC: −1.17% (−1.99–−0.37%), p = 0.

Sub-group analysis in relation to gender revealed a highly significant influence of ERα expression on OS and RFS in males but not in females, both for the ERα-positive primary tumor cohort (males: p = 0.0013; p < 0.0001; females: p = 0.56; p = 0.89) and the ERα-positive primary tumor/primary lymph node metastasis cohort (males: p < 0.0001; p < 0.0001; females: p = 0.95; p = 0.96).

Kaplan–Meier survival performed on all IHC subgroups revealed that an overall log-rank test was highly significant for both PFS ( p = 0.0017, Figure 3 B left) and SOS ( p = 0.0081, Figure 3 B right).

The HER2-low group demonstrated superior outcomes for DFS ( p = 0.0130), DMFS ( p = 0.0300), OS ( p = 0.0120), and particularly for BCSS, which showed a markedly significant difference ( p = 0.0019) ( Figure 4 ). 3.3.

Both pCEA and pCA 19-9 markers demonstrated highly significant discriminatory ability (respectively, p -value = 0.002 and p < 0.001).